Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study

References

• Yu XQ, Chen WH, O’Connell DL. Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. BMC Cancer 2010;10:231.
   PubMed Web of Science ®Google Scholar
• Keegan TH, McClure LA, Foran JM, . Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study. J Clin Oncol 2009;27:3044–3051.
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008;168:469–476.
   PubMed Web of Science ®Google Scholar
• Foran JM, McClure LA, Clarke CA, . Impact of socioeconomic status and race/ethnicity on survival in diffuse large B-cell lymphoma (DLBCL): a population-based study. Blood 2009;114(Suppl. 1): Abstract 1954.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-Hodgkin's lymphoma (version 1.2005) [Internet]. Available from: www.nccn.org/professionals/physician_gls/PDF/nhl.pdf
   Google Scholar
• National Cancer Institute. Adult non-Hodgkin's lymphoma (PDQ): treatment (health professional version) [Internet]. Available from: http://www.cancer.gov/cancerinfo/pdq/treatment/adult-non-hodgkins/healthprofessional
   Google Scholar
• Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 2003;121:44–48.
   PubMed Web of Science ®Google Scholar
• Fisher RI, LeBlanc M, Press OW, . New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, . Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–1992.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, . Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Pozzi S, Marcheselli L, . Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007;109:2077–2082.
   PubMed Web of Science ®Google Scholar
• van Oers MH. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 2007;92:826–833.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, . Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–4423.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 2002;29:25–29.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, . Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Hars V, Conaway MR, . Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr 1997;65:1495–1501.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
   PubMedGoogle Scholar
• Oken MM, Creech RH, Tormey DC, . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 2003;9:393–400; quiz 401–392.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD. Non-Hodgkin's lymphoma clinical practice guidelines. J Natl Compr Canc Netw 2004;2:286–336.
   PubMedGoogle Scholar
• Pazdur R. 2011 FDA approval for rituximab. In: Cancer drug information. National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-rituximab
   Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, . Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202–1208.
   PubMed Web of Science ®Google Scholar
• Mead GM, Barrans SL, Qian W, . A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008;112:2248–2260.
   PubMed Web of Science ®Google Scholar
• Link BK, Brooks J, Wright K, . Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma 2011;52:994–1002.
   PubMed Web of Science ®Google Scholar
• Griffiths R, Gleeson M, Knopf K, . Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer 2010;10:625.
   PubMed Web of Science ®Google Scholar
• Shih YC, Elting LS, Halpern MT. Factors associated with immunotherapy use among newly diagnosed cancer patients. Med Care 2009;47:948–958.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, . Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21–26.
   PubMed Web of Science ®Google Scholar
• Persky DO, Unger JM, Spier CM, . Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258–2263.
   PubMed Web of Science ®Google Scholar
• Cronin DP, Harlan LC, Clegg LX, . Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol 2005;23:73–81.
   PubMed Web of Science ®Google Scholar
• Schoenborn CA. Marital status and health: United States, 1999–2002. Adv Data 2004:1–32.
   PubMedGoogle Scholar
• Manzoli L, Villari P, Pironi GM, . Marital status and mortality in the elderly: a systematic review and meta-analysis. Soc Sci Med 2007;64:77–94.
   PubMed Web of Science ®Google Scholar
• Johnson NJ, Backlund E, Sorlie PD, . Marital status and mortality: the national longitudinal mortality study. Ann Epidemiol 2000;10:224–238.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Byrtek M, Taylor MD, . Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study. Cancer 2012;2012:27513.
   Google Scholar
• Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445–1476.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, . NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010;8:288–334.
   PubMed Web of Science ®Google Scholar
• Dotan E, Aggarwal C, Smith MR, . Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P T 2010;35:148–157.
   PubMedGoogle Scholar
• Roswall N, Olsen A, Christensen J, . Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994–2003. Eur J Cancer 2008;44:2058–2073.
   PubMed Web of Science ®Google Scholar
• Wang M, Burau KD, Fang S, . Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer 2008;113:3231–3241.
   PubMed Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F, . Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson CancerCenter. J Clin Oncol 2006;24:1582–1589.
   Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Krol AD, le Cessie S, Snijder S, . Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. Leuk Lymphoma 2003;44:451–458.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, . The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504–1508.
   PubMed Web of Science ®Google Scholar
• Diamond C, Taylor TH, Anton-Culver H. Characteristics and survival of patients with non-Hodgkin's lymphoma with and without acquired immunodeficiency syndrome. Hematol Oncol 2002;20: 177–187.
   PubMed Web of Science ®Google Scholar
• Clarke C, O’Malley CD. Non-Hodgkin lymphoma. In: Ries LAG, Young JL, Keel GE, ., editors. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. Bethesda: National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; 2007. pp. 237–242.
   Google Scholar
• Spina M, Gloghini A, Tirelli U, . Therapeutic options for HIV-associated lymphomas. Expert Opin Pharmacother 2010;11:2471–2481.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, . Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008;140:411–419.
   PubMed Web of Science ®Google Scholar